Ropinirole-induced symptomatic sinus node dysfunction

PACE - Pacing and Clinical Electrophysiology

Volumn 31, Issue 8, 2008, Pages 1079-1082

  Szymanski, Catherine ^a   Boey, Serge ^b   Hermida, Jean S ^a  

^a AMIENS UNIVERSITY HOSPITAL   (France)

^b Saint Quentin General Hospital   (France)

Author keywords

Ropinirole; Sinus node dysfunction; Syncope

Indexed keywords

ROPINIROLE;

ADULT; ARTICLE; CASE REPORT; CLINICAL EXAMINATION; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; FEMALE; HEART ELECTROPHYSIOLOGY; HEMODYNAMICS; HOSPITALIZATION; HUMAN; LABORATORY TEST; PACEMAKER; RESTLESS LEGS SYNDROME; SINUS NODE DYSFUNCTION; SINUS RHYTHM; SYNCOPE;

DOPAMINE AGONISTS; FEMALE; HUMANS; INDOLES; MIDDLE AGED; RESTLESS LEGS SYNDROME; SYNCOPE; TACHYCARDIA, SINUS;

EID: 48249120775     PISSN: 01478389     EISSN: 15408159     Source Type: Journal    
DOI: 10.1111/j.1540-8159.2008.01141.x     Document Type: Article

References (15)

1. Ondo W. Ropinirole for restless legs syndrome. Mov Disord 1999 14 : 138 140.
2. Bliwise DL, Freeman A, Ingram CD, Rye DB, Chakravorty S, Watts RL. Randomized, double-blind, placebo-controlled, short-term trial of ropinirole in restless legs syndrome. Sleep Med 2005 6 : 141 147.
3. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med 2000 342 : 1484 1491.
4. Trenkwalder C, Garcia-Borreguero D, Montagna P, Layney E, De Weerd AW, Tidswell P, Saletu-Zyhlarz G, et al. Ropinirole in the treatment of restless legs syndrome: Results from the TREAT RLS 1 study, a 12 week, randomised, placebo controlled study in 10 European countries. J Neurol Neurosurg Psychiatry 2004 75 : 92 97.
5. Lautsen G, Gilbert M, Wimett L. A look back at the most influential drug approvals of 2005. Nurse Pract 2006 31 : 26 41.
6. Chokroverty S. Editorial. Editor's corner: Restless legs syndrome, a common disease uncommonly diagnosed. Sleep Med 2003 4 : 91 93.
7. Olanow CW. An introduction to the free radical hypothesis in Parkinson's disease. Ann Neurol 1992 32 : S2 S9.
8. Kaye CM, Nicholls B. Clinical pharmacokinetics of ropinirole. Clin Pharmacolkinet 2000 39 : 243 254.
9. Uitti RJ, Ahlskog E. Comparative review of dopamine receptor agonists in Parkinson's disease. CNS Drugs 1996 5 : 369 388.
10. Ogawa N. Levodopa and dopamine agonists in the treatment of Parkinson's disease: Advantages and disadvantages. Eur Neurol 1994 34 (Suppl 3 20 28.
11. Eden RJ, Wallduck MS, Patel B, Owen DA. Autonomic and haemodynamic responses to SK & F 101468 (ropinirole), a DA2 agonist, in anaesthetised cats. Eur J Pharmacol 1990 175 : 333 334.
12. Adler CH, Sethi KD, Hauser RA, Davis TL, Hammerstad JP, Bertoni J, Taylor RL, et al. Ropinirole for the treatment of early Parkinson's disease. Neurology 1997 49 : 393 399.
13. Matheson AJ, Spencer CM. Ropinirole. A review of its use in the management of Parkinson's disease. Drugs 2000 60 : 115 137.
14. Brunt ER, Brooks DJ, Korczyn AD, Montasruc JL, Stocchi F. A six-month multicenter, double-blind, bromocriptine-controlled study of the safety and efficacity of ropinirole in the treatment of patients with Parkinson's disease not optimally controlled by L-dopa. J Neural Transm 2002 109 : 489 502.
15. 2 agonist, as sole dopaminergic therapy in Parkinson's disease. Clin Neuropharmacol 1998 21 : 101 107.